



## GW Institutional Biosafety Committee Meeting

Date: 11/19/2025

4:00 PM

Zoom

### Members Present:

P.Brindley, L. Dubrovsky, M. Firmani, M. Ghosh, L. Hopkins, J. Prigge

### Members Absent:

T. Bobo, K. Michel, D. Shau, A.Villagra

### Minutes

I. Call to order: The meeting was called to order at 4:03 PM once we had quorum.

II. Previous meeting minutes: The minutes of the October 15, 2025 meeting were reviewed and approved.

<b>Total votes For:</b>	6	<b>Total votes Absent:</b>	4	<b>Against:</b>	0
<b>Conflict of Interest:</b>	0	<b>Not present For Vote:</b>	0	<b>Abstained:</b>	0

III. Other business

**Invited guests:** Dr. Chang

**Invited guests present:** Dr. Juan Alzate (Chang lab)

**Incident reporting:** There were no incidents to report since the October 15, 2025 meeting.

**Protocols approved since last meeting:** #25-307 (Brindley), #25-303 (Grayfer), & #25-305 (Huff)

**New Business discussed:**

- Dr. Chang's protocol #25-308
- **Approved Amendments:**
  - 5 amendments were administratively approved
- **Approved Annual Reviews:**
  - 4 annual reviews were administratively approved

**Next Meeting:** December 17, 2025

**Adjourn:** Meeting was adjourned at 4:22 PM

**Minutes taken by:** IBC Administrator

### III. Submission Review

**New Protocols:**

Principal Investigator:	Aileen Chang, MD, MSPH
IBC #	IBC-25-308
Study Title:	Zanamivir treatment of vascular Permeability in Dengue (ZAP-DENGUE)
Category:	N/A
BSL:	2
ABSL:	N/A
Enhanced:	No
Submission Outcome:	Conditionally approved (administrative review)
Notes:	

**Summary of Dr. Chang's research:** ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever. Their central hypothesis is that zanamivir treatment is safe in patients with dengue infection, will significantly decrease serum sialic acid levels, and will result in fewer patients with the development of moderate or severe clinical plasma leakage. To see whether the drug is working, blood samples from 74 study participants in Northern Columbia are collected at six different times during their illness. These samples will be sent to GW to measure sialic acid levels.

**Committee discussion about Dr. Chang's protocol:** The designated reviewers presented their review. Overall the committee agreed that the protocol was well written. Most of the comments were about decontamination procedures and containment of aerosols. A reviewer noted that the contact time for bleach treatment was not indicated. In addition, the 1:10 bleach dilution was incorrect in the surface decontamination section. Clarification regarding the removal of gloves in the BSC was needed. The committee was not sure if decontamination of the BSC and items inside was done before glove removal. In addition to clarification, the committee also strongly recommended the use of double gloves when working in the BSC.

**Motion:** To conditionally approve (administrative review) pending the completion of the requested revisions listed in the iRIS system.

<b>Total votes For:</b>	6	<b>Total votes Absent:</b>	4	<b>Against:</b>	0
<b>Conflict of Interest:</b>	0	<b>Not present For Vote:</b>	0	<b>Abstained:</b>	0